About Zucara Therapeutics
Zucara Therapeutics is a company based in Vancouver (Canada) founded in 2015. Zucara Therapeutics has raised $50.82 million across 12 funding rounds from investors including Sanofi, National Research Council Canada and Mitacs. The company has 12 employees. Zucara Therapeutics offers products and services including Hypoglycemia Therapeutic. Zucara Therapeutics operates in a competitive market with competitors including Neurocrine, Crinetics, MBX Biosciences, Radionetics and Siolta Therapeutics, among others.
- Total Equity Funding$50.82M (USD)
in 12 rounds
- Latest Funding Round$5M (USD), Series B
Feb 2025
- InvestorsSanofi
& 12 more
- Employee Count12
Products & Services of Zucara Therapeutics
Zucara Therapeutics offers a comprehensive portfolio of products and services, including Hypoglycemia Therapeutic.
Once-daily drug to prevent low blood sugar in diabetes patients.
Funding Insights of Zucara Therapeutics
Zucara Therapeutics has successfully raised a total of $50.82M across 12 strategic funding rounds. The most recent funding activity was a Series B round of $5 million completed in February 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $50.82M
- Total Rounds 12
- Last Round Series B β $5M
- Investors Count 13
Latest 10 of 12 funding rounds of Zucara Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2025 | $5M | Series B | β | β | |
| Nov 2024 | $20M | Series B | β | Sanofi | |
| May 2022 | – | Grant | β | β | |
| Nov 2020 | – | Grant | β | β | |
| Mar 2020 | $21M | Series A | β | Perceptive Advisors | β |
| Apr 2018 | $3.9M | Series A | β | β | |
| Feb 2018 | $400,000 | Seed | β | Cdrd.ca, TIAP | β |
| Feb 2018 | $350,000 | Grant | β | β | |
| Sep 2017 | – | Seed | β | β | |
| Nov 2016 | $525,000 | Seed | β | Accel-Rx, Cdrd.ca | β |
13 investors in total: 13 institutional.
Investors in Zucara Therapeutics
Zucara Therapeutics has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Sanofi, National Research Council Canada and Mitacs.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Companies developing T1D products are funded through venture philanthropy. | – | t1dfund.org | Boston, United States | |
Life science startups are accelerated through focused programs by Xontogeny. | 2016 | xontogeny.com | Boston, United States | |
A charitable trust focused on healthcare and research funding. | – | helmsleytrust.org | New York, United States | |
Early-stage health science technologies are developed into business ventures by TIAP. | – | tiap.ca | Toronto, Canada | |
- | – | accel-rx.com | - | |
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Pharmaceutical and nutraceutical products are developed across seven therapeutic areas. | 1973 | sanofi.com | Paris, France | |
A foundation focused on economic development | 1999 | mitacs.ca | Montreal, Canada | |
Research and innovation in glycomics are advanced by GlycoNet. | 2015 | canadianglycomics.ca | Edmonton, Canada | |
Scientific and technological research is conducted for Canada's benefit. | 1916 | nrc.canada.ca | Ottawa, Canada |
Investor details for Zucara Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Zucara Therapeutics
4 people are tracked at Zucara Therapeutics (2 in leadership, 2 in team); the tracked headcount is 12.
| Name | Role | Group |
|---|---|---|
Michael Midmer | Chief Executive Officer | Leadership |
Richard Liggins | Co Founder & Chief Scientific Officer | Leadership |
Eric Simonson | Senior Manager, Scientific Programs | Team |
Almira Blazek-Welsh | Senior Manager, CMC Operations | Team |
Complete people profiles for Zucara Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Zucara Therapeutics
3 dated milestones of Zucara Therapeutics across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Zucara Therapeutics is founded.
- Funding First funding round.
- Funding Latest funding round, Series B, of $5.0M.
Competitors of Zucara Therapeutics
Zucara Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Neurocrine, Crinetics, MBX Biosciences, Radionetics and Siolta Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders | |
| crinetics.com | 2008 | San Diego, United States | $103.5M | 120 | Developer of therapies for the treatment of endocrine-related diseases and cancers | |
| mbxbio.com | 2018 | Carmel, United States | $215.6M | 11 | Drugs for rare endocrine diseases are developed and advanced. | |
| radionetics.com | 2021 | San Diego, United States | $136.71M | – | Peptide-targeted radiopharmaceuticals for cancer treatment are developed. | |
| sioltatherapeutics.com | 2016 | San Francisco, United States | $42M | – | Microbiome therapeutics are provided for treating chronic inflammatory diseases. | |
| diasome.com | 2005 | Cleveland, United States | $72.63M | – | Developer of therapies for the treatment of diabetes and other metabolic conditions | |
| vikingtherapeutics.com | 2012 | California, United States | $2.5M | 27 | Small molecule therapies for endocrine and metabolic disorders are developed. | |
| millendo.com | 2012 | Ann Arbor, United States | $102.77M | 30 | Immune-mediated targeted therapies for cancer are developed. |
Detailed competitors of Zucara Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Zucara Therapeutics
Complete news archive for Zucara Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Zucara Therapeutics
10 companies that operate in the same segment as Zucara Therapeutics (Metabolic Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Developer of cortisol modulators for the treatment of various diseases | 1998 | Menlo Park, California, United States | – | USD 761.41 M | 500 | |
Developer of therapies for the treatment of endocrine-related diseases and cancers | 2008 | San Diego, California, United States | USD 103.5 M | USD 1.04 M | 437 | |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | 2009 | Cambridge, Massachusetts, United States | USD 685 M | – | 81 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Solutions for biomarker discovery and diagnostic testing are provided. | 2000 | Morrisville, United States | USD 165.87 M | – | – | |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. | 2007 | Fremont, California, United States | USD 61.1 M | USD 407.32 M | 395 | |
Biologics are developed for cardio-metabolic and liver diseases. | 2007 | San Francisco, California, United States | USD 358.87 M | USD 330.53 M | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Zucara Therapeutics
Zucara Therapeutics was founded in 2015.
Zucara Therapeutics is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.
Zucara Therapeutics is a funded company, having raised a total of $50.82M across 12 funding rounds to date. The company's 1st funding round was a Seed of $525K, raised on Jun 2015.
Zucara Therapeutics has 12 employees.
Zucara Therapeutics, a spin-off of The Centre for Drug Research and Development (CDRD) and MaRS Innovation (MI), is developing a novel drug for the treatment of hypoglycemia associated with insulin therapy. Their lead candidate PRL-2903 works via the chronic receptor antagonism through which they block somatostatin type 2 (SSTR2) receptors on Ξ±-cells in the pancreas.
Zucara Therapeutics's top competitors include Crinetics, Neurocrine and MBX Biosciences.
Zucara Therapeutics offers Hypoglycemia Therapeutic.
Zucara Therapeutics has 13 investors. Key investors include Sanofi, National Research Council Canada, Mitacs, Perceptive Advisors, and Canadian Space Agency.
Zucara Therapeutics operates through Zucara Therapeutics Inc..